Neuroscience 2000 Abstract
| Presentation Number: | 812.12 |
|---|---|
| Abstract Title: | The effect of the cannabinoid HU-210 on rat learning and spinal nociception. |
| Authors: |
Schechter, J. B.*1
; Cruce, W. L. R.1
; McBurney, D. L.1
; Stuesse, S. L.1
; Crisp, T.1
1Pain Interest Group, Northeastern Ohio Universities College of Medicine, Rootstown, OH |
| Primary Theme and Topics |
D. Neurotransmitters, Modulators, Transporters, and Receptors - 54. Cannabinoids |
| Secondary Theme and Topics | F. Sensory Systems<br />- 75. Pain modulation: pharmacology |
| Session: |
812. Cannabinoids: analgesia Poster |
| Presentation Time: | Thursday, November 9, 2000 11:00 AM-12:00 PM |
| Location: | Hall G-J |
| Keywords: | Pain, Discrimination, Paw - Withdrawal, Tail - Flick |
The potent exocannabinoid agonist (-)-8-tetrahydrocannabinol-dimethyl-heptyl (HU-210) was examined for discriminative, analgesic, antihyperalgesic and antiallodynic efficacy in the rat. Discriminative potential was evaluated by utilizing the drug discrimination paradigm. The analgesic effect of intrathecally-administered (IT) HU-210 was assessed on the tail-flick latency (TFL) and paw-withdrawal latency (PWL) paradigms. Antihyperalgesic and antiallodynic effects were assessed by use of an inflammatory model -- intraplantar 1% type IV lambda carrageenan -- and thermal and tactile sensitivity were measured via a thermal plantar analgesic meter and von Frey filaments, respectively.
Intraperitoneally administered HU-210 (0.06 mg kg-1) evoked a discriminative performance in which 90% of all lever selections were made on the HU-210-appropriate lever (p≤0.01). The HU-210-appropriate lever was selected in 3.3% of all trials following vehicle administration. A complete, dose-responsive blockade of HU-210 discrimination was produced by coadministration of the specific cannabinoid antagonist SR 141716A (1.875-3.75 mg kg-1 IP; p≤0.05).
HU-210 administered IT at 25.86 nmol (10 μg; in DMSO) was significantly analgesic (TFL) between 10 and 120 minutes post-administration (p≤0.023, 0.035; n=8, 8). A 2.586 nmol (1 μg) dose was significantly analgesic (PWL) at 60 minutes (p≤0.03; n=8). Spinal HU-210-induced analgesia was reversed by coadministration of SR141716A (1 mg kg-1 IP) in the TFL and PWL paradigms (p≤0.001), thus suggesting that HU-210 induces both a discriminable CB1-mediated interoceptive behavioral cue as well as significant spinal analgesia.
Intraperitoneally administered HU-210 (0.06 mg kg-1) evoked a discriminative performance in which 90% of all lever selections were made on the HU-210-appropriate lever (p≤0.01). The HU-210-appropriate lever was selected in 3.3% of all trials following vehicle administration. A complete, dose-responsive blockade of HU-210 discrimination was produced by coadministration of the specific cannabinoid antagonist SR 141716A (1.875-3.75 mg kg-1 IP; p≤0.05).
HU-210 administered IT at 25.86 nmol (10 μg; in DMSO) was significantly analgesic (TFL) between 10 and 120 minutes post-administration (p≤0.023, 0.035; n=8, 8). A 2.586 nmol (1 μg) dose was significantly analgesic (PWL) at 60 minutes (p≤0.03; n=8). Spinal HU-210-induced analgesia was reversed by coadministration of SR141716A (1 mg kg-1 IP) in the TFL and PWL paradigms (p≤0.001), thus suggesting that HU-210 induces both a discriminable CB1-mediated interoceptive behavioral cue as well as significant spinal analgesia.
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2000 Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience, 2000. Online.
Copyright © 2000-2025 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
